Standard Drug Discovery and Development

$1 to $2 billion

Cost of a new drug development

10 to 15 years

To develop a new drug

1:10k

Success rate

We can reduce those numbers to

$250k – $50M

Cost of a new drug development

4 to 5 years

To develop a new drug

3:10

Success rate

OUR APPROACH

Artificial Intelligence

Propietary Databases of Chemical Structures

Scientific Expertise

Our Directions of Work

Proprietary pipeline

Proprietary pipeline

PARTNERSHIP

Our performance indicators

12%

of our performed projects have
reached Clinical Phase 2

29%

of our projects have a positive
in vitro lead

We cooperate with

SOM Biotech in the media

LATEST NEWS

SOM Biotech granted Orphan Drug Designation by the FDA for SOM3355
October 18, 2021

~SOM3355 has the potential to be an alternative to current VMAT2 inhibitors with a significantly improved side effect profile for the treatment of chorea in Huntington´s disease~  SOM Biotech (“SOM” or the “Company”), a clinical-stage drug discovery and development company focused on orphan diseases of the Central Nervous System, today ...

SOM Biotech presents positive Phase 2a data with SOM3355
SOM Biotech presents positive Phase 2a data with SOM3355 at the 34thECNP Congress 2021
October 4, 2021

~Data show SOM3355 reduces chorea in patients with Huntingdon’s Disease and has a good safety profile~ ~SOM3355 discovered through SOM Biotech’s proprietary artificial intelligence-based computational technology SOMAI PRO~ SOM Biotech today announces it will be presenting positive Phase 2a data with SOM3355, an oral vesicular monoamine transporter 2 (VMAT2) inhibitor ...

Artificial Intelligence in Healthcare
SOM Biotech performed a presentation at the University of Barcelona Summer Course dedicated to Rare Diseases
July 28, 2021

SOM Biotech performed a presentation at the University of Barcelona Summer Course dedicated to Rare Diseases. The course was held from the 5th to the 9th of July. Dr. Raúl Insa, CEO of the company, performed the presentation on the topic of drug repurposing for Rare Diseases. The main objective ...

SOM Biotech recognized as an innovative company by the Ministry of Science and Innovation
July 5, 2021

SOM Biotech announces that it has obtained an INNOVATIVE SME seal from the Ministry of Science and Innovation. This distinction recognizes SOM Biotech’s contribution to R&D innovation. The accreditation highlights the innovative business model, based on a pioneering computational chemistry technology that the company has developed to accelerate and streamline ...

Artificial Intelligence in Healthcare
SOM Biotech appoints Marc Casellas as Chief Financial Officer
June 28, 2021

SOM Biotech announces the appointment of Marc Casellas as Chief Financial Officer. Mr Casellas has an extensive finance experience across the healthcare and venture capital sectors, especially in providing financing to life science companies at different stages of growth. Prior to joining SOM Biotech, Marc Casellas most recently served as ...

SOM Biotech to participate at the BIO International Convention 2021
May 27, 2021

SOM Biotech announces its participation in the BIO International Convention 2021 on June 10th – 18th, that will take place digitally. Hosted by the Biotechnology Innovation Organisation, the event is the largest global event for the biotechnology industry that attracts the leading biotech companies, scientists, research institutions, advisors, and qualified ...

SOM Biotech to participate at the BIO-Equity Europe 2021
May 13, 2021

SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17th – 19th, which will take place digitally. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotech companies as well as specialized investors in life sciences. The event enables ...

SOM3355 for chorea in Huntington´s disease
SOM Biotech announces a presentation of the Phase 2 clinical results of SOM3355 for the treatment of chorea in Huntington´s disease
April 22, 2021

SOM Biotech will present results from the Phase 2 clinical study of SOM3355 for the treatment of chorea symptoms in Huntington´s disease at the XXVI World Congress on Parkinson’s Disease and Related Disorders, to be held May 1st – 4th 2021. The International Association for Parkinsonism and Related Disorders (IAPRD) ...